We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

83 hedge funds and large institutions have $4.79M invested in VistaGen Therapeutics in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 18

1% more capital invested

Capital invested by funds: $4.75M → $4.79M (+$38.4K)

0.07% less ownership

Funds ownership: 0.66% → 0.58% (-0.07%)

8% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 13

2% less funds holding

Funds holding: 85 → 83 (-2)

Holders
83
Holders Change
-2
Holders Change %
-2.35%
% of All Funds
1.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
24
Reduced
18
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$163K
2
State Street
State Street
Massachusetts
+$47.1K
3
Allspring Global Investments
Allspring Global Investments
North Carolina
+$37.1K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$36.4K
5
HNWA
Henrickson Nauta Wealth Advisors
Michigan
+$35K

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$668K
2
N
Nuveen
North Carolina
-$597K
3
Two Sigma Investments
Two Sigma Investments
New York
-$57.6K
4
Citadel Advisors
Citadel Advisors
Florida
-$37K
5
Morgan Stanley
Morgan Stanley
New York
-$11.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
ProShare Advisors
51
ProShare Advisors
Maryland
$3.04K -$399 -76 -9%
Victory Capital Management
52
Victory Capital Management
Texas
$3.03K +$4.25K +811 New
Cambridge Investment Research Advisors
53
Cambridge Investment Research Advisors
Iowa
$3K -$205 -39 -4%
JWM
54
Jackson Wealth Management
Florida
$2.97K +$4.17K +795 New
FAIM
55
Financial Advocates Investment Management
Washington
$2.88K – – –
Legal & General Group
56
Legal & General Group
United Kingdom
$2.58K – – –
UBV
57
United Bank (Virginia)
Virginia
$2.5K – – –
CTA
58
Chesley Taft & Associates
Illinois
$2.49K – – –
PAM
59
Panagora Asset Management
Massachusetts
$2.42K +$3.39K +647 New
Citadel Advisors
60
Citadel Advisors
Florida
$2.2K -$37K -7,061 -92%
Carson Wealth (CWM LLC)
61
Carson Wealth (CWM LLC)
Nebraska
$2K – – –
Mariner
62
Mariner
Kansas
$2K – – –
MML Investors Services
63
MML Investors Services
Massachusetts
$2K – – –
HFM
64
Hartford Financial Management
Connecticut
$2K – – –
BFG
65
Bleakley Financial Group
New Jersey
$1.88K +$89 +17 +4%
SS
66
Simplicity Solutions
Minnesota
$1.88K +$89 +17 +4%
AIP
67
Ameritas Investment Partners
Nebraska
$1.87K – – –
Mackenzie Financial
68
Mackenzie Financial
Ontario, Canada
$1.71K – – –
EA
69
Echo45 Advisors
California
$1.63K -$456 -87 -17%
GCA
70
Genesee Capital Advisors
New York
$1.58K -$1.26K -241 -36%
TLCM
71
Twin Lakes Capital Management
California
$1.56K – – –
BWM
72
Boyd Wealth Management
California
$1.52K – – –
State Board of Administration of Florida Retirement System
73
State Board of Administration of Florida Retirement System
Florida
$1.45K – – –
X
74
Xponance
Pennsylvania
$1.42K – – –
Ameriprise
75
Ameriprise
Minnesota
$1.35K +$1.9K +362 New
1 2
3
4

VTGN Hedge Fund Activity: Q1 2023 in Review

83 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2023, worth a combined $4.79M — up 0.81% from $4.75M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of VTGN and 12 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 24 added.

The largest buyer was BlackRock, adding an estimated $163K. The largest seller was GSA Capital Partners, cutting an estimated $668K.

  • 83 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2023, down from 85 in Q4 2022.
  • Funds reported $4.79M of VistaGen Therapeutics stock for Q1 2023, up 0.81% quarter-over-quarter.
  • 12 funds opened new VistaGen Therapeutics positions in Q1 2023 and 13 closed out, a net change of -1 holder.
  • The largest VistaGen Therapeutics buyer in Q1 2023 was BlackRock, an estimated $163K added.
  • The largest VistaGen Therapeutics seller in Q1 2023 was GSA Capital Partners, an estimated $668K sold.

Based on aggregated 13F filings for Q1 2023.